A KRAS gén mutáció analízise nem kissejtes tüdőrákban és colorectális carcinómában
, 2016 A daganatos megbetegedések és halálozások igen magas gyakorisága komoly népegészségügyi probléma világszerte, így hazánkban is. A legtöbb áldozatot követelő daganatféleségek közül diplomadolgozatom elkészítése során a nem kissejtes tüdőrák és ...
Gazdag, Annamária
core
Flywheel inertial actuator for velocity feedback control: parametric study
, 2016 This paper presents a new proof mass actuator for the implementation of decentralised velocity feedback control loops to reduce the flexural vibration of a thin plate structure at low audio frequencies.
KRAS, Aleksander Stefan, GARDONIO, Paolo
core +1 more source
Evaluation of BRAF and KRAS Gene Expression in Nasal Polyposis [PDF]
Objective: The goal of this study was to investigate the expression patterns and potential relationship of the Kirsten rat sarcoma viral oncogene homolog (KRAS) and B-raf proto-oncogene (BRAF) genes in nasal polyposis (NP). Methods: Twenty-nine patients
Halil İbrahim Yıldırım +4 more
core +1 more source
Escaping KRAS: Gaining Autonomy and Resistance to KRAS Inhibition in KRAS Mutant Cancers
, 2021 Activating mutations in KRAS are present in 25% of human cancers. When mutated, the KRAS protein becomes constitutively active, stimulating various effector pathways and leading to the deregulation of key cellular processes, including the suppression of ...
Kentaro Hirade +3 more
core +1 more source
Targeting mutant KRAS in human colon cancer cells through G-quadruplex ligands
, 2014 Teses de mestrado, Ciências Biofarmacêuticas, Universidade de Lisboa, Faculdade de Farmácia, 2014KRAS mutations occur in 35 to 45% of colon tumors, being an important target for cancer treatment, for which there are no targeted therapeutics available ...
Brito, Hugo Miguel de Sousa e
core
New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness. [PDF]
, 2019 In non-small cell lung cancer (NSCLC), the most frequent oncogenic mutation in western countries is KRAS, for which, however, there remains no clinically approved targeted therapies. Recent progress on high biological heterogeneity including diverse KRAS
Peng, Ren-Wang +3 more
core +2 more sources
KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer [PDF]
, 2012 BACKGROUND: Three quarter of endometrial carcinomas are treated at early stage. Still, 15 to 20% of these patients experience recurrence, with little effect from systemic therapies.
Mjøs, Siv +31 more
core +1 more source
CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C+ NSCLC Enigma Code
, 2023 Danielle Brazel,1 Jennifer Kim,1 Sai-Hong Ignatius Ou1,2 1University of California Irvine School of Medicine, Department of Internal Medicine, Division of Hematology-Oncology, Orange, CA, USA; 2Chao Family Comprehensive Cancer Center, Orange, CA ...
Brazel D, Kim J, Ou SI
core
Internalising radioimmunoconjugates to target KRas cancer cells for simultaneous radio-ligand therapy and radiosensitisation [PDF]
The intracellular environment hosts many cancer-relevant proteins. Among them, Ras plays an important role and is frequently activated in cancers of unmet need, such as pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancers (NSCLC) and ...
Lourenço, João
core +1 more source
Dinamički kontaktni kut u funkciji karakterizacije tiskovnih formi
, 2009 Dinamički kontaktni kut praćen je na tiskovnim i slobodnim površinama ofsetne tiskovne forme pri čemu su korištene tri kapljevine definirane disperzne i polarne faze (voda, glicerol i dijodometan).
Guljelmović, Dino
core +1 more source